Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration

被引:5
|
作者
Kumar, Atul [1 ]
Mann, Henry J. [2 ]
机构
[1] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA
[2] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
关键词
Antiinfective agents; Color; Concentration; Dextrose; Diluents; Hydrogen ion concentration; Incompatibilities; Injections; Oritavancin diphosphate; Precipitation; Stability; Storage;
D O I
10.2146/ajhp100011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The visual compatibility of the new intravenous antibiotic oritavancin diphosphate with various drugs commonly administered to patients in acute care settings was studied. Methods. Clinically used concentrations of 37 drugs, including antibiotics, sedatives, analgesics, and cardiovascular agents, were evaluated in 1:1 mixtures with oritavancin concentrations of 0.8, 1.2, and 2 mg/mL. Oritavancin solutions were prepared in 5% dextrose injection and mixed with each test drug solution. The mixtures were then visually observed over a period of four hours at room temperature. The pH of the mixtures was also determined immediately and four hours after mixing. Compatibility was defined as the absence of any color change, haze, fibers, particles, and precipitate. Results. Of the 37 tested drugs, 23 were visually compatible with all three concentrations of oritavancin over the four-hour study period. Drugs formulated at a basic or neutral pH were more likely to be incompatible with oritavancin. Conclusion. Oritavancin diphosphate was visually incompatible with many intravenous drugs that are likely to be coadministered in acute care settings.
引用
收藏
页码:1640 / 1644
页数:5
相关论文
共 50 条
  • [1] Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration
    Du Repaire, Theau
    Vigne, Petula
    Guedon, Amaury
    Fanciullino, Raphaelle
    Gauthier-Villano, Laurence
    Peres, Pierre Bertault
    Pourroy, Bertrand
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (16) : 1217 - 1218
  • [2] Visual compatibility of defibrotide with selected drugs during simulated Y-site administration
    Correard, Florian
    Savry, Amandine
    Gauthier-Villano, Laurence
    Pisano, Pascale
    Pourroy, Bertrand
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (15) : 1288 - 1291
  • [3] COMPATIBILITY OF FILGRASTIM WITH SELECTED DRUGS DURING SIMULATED Y-SITE ADMINISTRATION
    TRISSEL, LA
    MARTINEZ, JF
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (15): : 1907 - 1913
  • [4] COMPATIBILITY OF AZTREONAM WITH SELECTED DRUGS DURING SIMULATED Y-SITE ADMINISTRATION
    TRISSEL, LA
    MARTINEZ, JF
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (10) : 1086 - 1090
  • [5] COMPATIBILITY OF AMIFOSTINE WITH SELECTED DRUGS DURING SIMULATED Y-SITE ADMINISTRATION
    TRISSEL, LA
    MARTINEZ, JF
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (20) : 2208 - 2212
  • [6] PHYSICAL COMPATIBILITY OF MELPHALAN WITH SELECTED DRUGS DURING SIMULATED Y-SITE ADMINISTRATION
    TRISSEL, LA
    MARTINEZ, JF
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1993, 50 (11): : 2359 - 2363
  • [7] Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration
    Trissel, LA
    Martinez, JF
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (09) : 1041 - 1045
  • [8] Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration
    Hall, PD
    Yui, D
    Lyons, S
    Bosso, JA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (02) : 185 - 189
  • [9] VISUAL COMPATIBILITY OF AMSACRINE WITH SELECTED DRUGS DURING SIMULATED Y-SITE INJECTION
    TRISSEL, LA
    CHANDLER, SW
    FOLSTAD, JT
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1990, 47 (11): : 2525 - 2528
  • [10] Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration
    Chan, Pak
    Bishop, Amanda
    Kuplec, Thomas C.
    Trissel, Lawrence A.
    Gole, Dilip
    Jimidar, Ilias M.
    Vermeersch, Hans
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (16) : 1545 - 1551